Karyopharm Therapeutics Stock (NASDAQ:KPTI)
Previous Close
$0.99
52W Range
$0.62 - $1.95
50D Avg
$0.80
200D Avg
$1.02
Market Cap
$112.61M
Avg Vol (3M)
$716.36K
Beta
0.20
Div Yield
-
KPTI Company Profile
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Performance
Peer Comparison
Ticker | Company |
---|---|
NUVB | Nuvation Bio Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
GOSS | Gossamer Bio, Inc. |
MREO | Mereo BioPharma Group plc |
HOOK | HOOKIPA Pharma Inc. |
BLUE | bluebird bio, Inc. |
CTMX | CytomX Therapeutics, Inc. |
GBIO | Generation Bio Co. |
REPL | Replimune Group, Inc. |
RLYB | Rallybio Corporation |
KRON | Kronos Bio, Inc. |
ASMB | Assembly Biosciences, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
AGIO | Agios Pharmaceuticals, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
MRSN | Mersana Therapeutics, Inc. |
NLTX | Neurogene Inc. |
LYRA | Lyra Therapeutics, Inc. |
NVCT | Nuvectis Pharma, Inc. |